VUNO Collaborates with European Firms for DeepCARS® Expansion
- Strategic MOU enhances market access and extends reach to over 900 hospitals across the region
In a significant move to enter the European healthcare market, VUNO Inc., a prominent global medical AI company based in South Korea, has entered into a strategic Memorandum of Understanding (MOU) with two notable European firms: Contextflow, an Austrian imaging AI company, and Mesalvo, a well-regarded German hospital information system provider. This partnership aims to jointly advance VUNO's AI-based cardiac arrest prediction solution, VUNO Med®–DeepCARS®.
Through this collaborative effort, VUNO is looking to tap into the strengths of both Contextflow and Mesalvo, leveraging their technological expertise to ensure a successful launch of DeepCARS in Europe. Contextflow brings in-depth knowledge of reimbursement and regulatory processes which is essential for navigating the competitive landscape of medical AI solutions. This will be critical for making DeepCARS compliant with European regulations while also enhancing its market access.
Mesalvo, with its extensive experience in hospital information systems across various European markets, will play a vital role in integrating DeepCARS into its electronic health record (EHR) systems. This step is significant, as it positions VUNO's solution to potentially reach over 900 hospitals, thereby maximizing its impact on patient care across the continent.
During the announcement of the MOU, VUNO showcased DeepCARS at a dedicated booth during the 38th Annual Congress of the European Society of Intensive Care Medicine, known as ESICM LIVES 2025. By adopting the motto "Predict Early, Prevent More," the company emphasized the innovative features of DeepCARS, illustrated through compelling real-world clinical scenarios that demonstrated the system’s superior predictive capabilities when compared to traditional early warning systems. This presentation attracted considerable attention from intensive care professionals.
Dr. Ye Ha Lee, Founder & CEO of VUNO, expressed excitement regarding this partnership, stating, "The signing of this strategic MOU is a significant milestone for our efforts at DeepCARS’ expansion into Europe. Collaborating with credible local partners is crucial to establishing a reliable global standard in AI-based patient care that European healthcare providers can trust."
About VUNO
Founded in 2014, VUNO is recognized as a leading medical AI company in South Korea, becoming the developer of the country's first FDA-approved AI-powered medical device. By harnessing advanced AI technology, VUNO analyzes an extensive array of medical data, ranging from bio-signals such as ECG, respiratory rate, and blood pressure to medical imaging, including X-rays and CT scans. This capability is geared toward predicting critical events and assisting clinicians in their decision-making processes. Committed to patient-centered innovation, the firm aims to democratize access to high-quality healthcare globally.
About VUNO Med®-DeepCARS®
VUNO Med®-DeepCARS® is an advanced AI-powered medical device crafted to monitor the risk of in-hospital cardiac arrest within a 24-hour window. The system assesses patients' vital signs, focusing on key metrics such as blood pressure, heart rate, respiratory rate, and body temperature, giving healthcare providers crucial insights into patient health in general wards.
Since its implementation in South Korea, DeepCARS has become integral to more than 50,000 hospital beds, including over 20 tertiary general hospitals, proving its reliability in critical patient care. In 2023, DeepCARS achieved Breakthrough Device Designation (BDD) from the U.S. Food and Drug Administration (FDA) and is currently in the process of securing FDA approval.
Frequently Asked Questions
What is the purpose of the strategic MOU signed by VUNO?
The strategic MOU aims to facilitate VUNO's entry into the European market with its AI cardiac arrest prediction solution, DeepCARS.
Who are VUNO's partners in this collaboration?
VUNO has partnered with Contextflow, an imaging AI company, and Mesalvo, a hospital information system provider, for this initiative.
How many hospitals could VUNO potentially reach in Europe?
Through its collaboration, VUNO aims to extend its reach to over 900 hospitals across Europe.
What features does DeepCARS offer?
DeepCARS analyzes vital signs to predict the risk of in-hospital cardiac arrest, providing critical insights to healthcare professionals.
What recognition has DeepCARS received?
DeepCARS has received Breakthrough Device Designation from the U.S. FDA and has been implemented in over 50,000 hospital beds in South Korea.
